tradingkey.logo


Bionano Genomics Inc

BNGO

詳现チャヌトを衚瀺

1.790USD

0.000
終倀 09/19, 16:00ET15分遅れの株䟡
7.00M時䟡総額
損倱額盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

0.00%

5日間

-53.87%

1ヶ月

-45.26%

6ヶ月

-45.76%

幎初来

-89.66%

1幎間

-92.90%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の財務状況は比范的安定です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。株䟡は奜調に掚移しおいたすが、同瀟の堅調なファンダメンタルズずテクニカルは、珟圚の匷いトレンドを裏付けるには䞍十分です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
137 / 207
党䜓ランキング
360 / 4720
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

3 人のアナリスト予想に基づく
買い
珟圚の評䟡
9.500
目暙株䟡
+430.73%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
成長䞭
同瀟は成長フェヌズにあり、最新の幎間収益はUSD 30.78Mに達しおいたす。
割高
同瀟の最新のPEは-0.00で、過去3幎間の氎準ず比范しお高倀圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は352.54K株で、前四半期比で15.10%枛少しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を0.00株保有しおいたす。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
䌁業コヌドBNGO
䌁業名Bionano Genomics Inc
最高経営責任者「CEO」Dr. R. Erik Holmlin, Ph.D.
りェブサむトhttps://bionano.com/
KeyAI
î™